[go: up one dir, main page]

WO2015065524A3 - Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells - Google Patents

Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells Download PDF

Info

Publication number
WO2015065524A3
WO2015065524A3 PCT/US2014/038993 US2014038993W WO2015065524A3 WO 2015065524 A3 WO2015065524 A3 WO 2015065524A3 US 2014038993 W US2014038993 W US 2014038993W WO 2015065524 A3 WO2015065524 A3 WO 2015065524A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
differentiation
clustering
suspension
pluripotent stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/038993
Other languages
French (fr)
Other versions
WO2015065524A2 (en
Inventor
Benjamin Fryer
Daina LANIAUSKAS
Marcia BLACKMOORE
Haiyun Wang
Kostadinka LILOVA
Shelley Nelson
Elizabeth ROSOCHA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/998,974 external-priority patent/US10377989B2/en
Priority to KR1020167014409A priority Critical patent/KR20160079072A/en
Priority to SG11201603045VA priority patent/SG11201603045VA/en
Priority to JP2016527338A priority patent/JP2016534731A/en
Priority to KR1020187034291A priority patent/KR20180128529A/en
Priority to MX2016005657A priority patent/MX2016005657A/en
Priority to AU2014342995A priority patent/AU2014342995C1/en
Priority to EP14857034.4A priority patent/EP3063268A4/en
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority to CA2928639A priority patent/CA2928639A1/en
Priority to RU2016121409A priority patent/RU2689710C2/en
Priority to CN201480059910.5A priority patent/CN105793413A/en
Publication of WO2015065524A2 publication Critical patent/WO2015065524A2/en
Publication of WO2015065524A3 publication Critical patent/WO2015065524A3/en
Priority to PH12016500782A priority patent/PH12016500782A1/en
Anticipated expiration legal-status Critical
Priority to AU2018208707A priority patent/AU2018208707A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C12N5/0075—General culture methods using substrates using microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/19—Growth and differentiation factors [GDF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The disclosure provides methods of preparing aggregated pluripotent stem cell clusters for differentiation to endoderm progenitor cells, pancreatic endocrine cells, mesoderm cells or ectoderm cells. Specifically, the disclosure provides methods of differentiating pluripotent cells into beta cell, cardiac cell and neuronal cell lineages using suspension clustering. The methods involve preparing the aggregated cell clusters followed by differentiation of these clusters.
PCT/US2014/038993 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells Ceased WO2015065524A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
RU2016121409A RU2689710C2 (en) 2013-11-01 2014-05-21 Suspending and clustering human pluripotent stem cells for their differentiation into pancreatic endocrine cells
CA2928639A CA2928639A1 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
JP2016527338A JP2016534731A (en) 2013-11-01 2014-05-21 Suspension and population of human pluripotent stem cells for differentiation into pancreatic endocrine cells
KR1020187034291A KR20180128529A (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
MX2016005657A MX2016005657A (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells.
AU2014342995A AU2014342995C1 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
EP14857034.4A EP3063268A4 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
KR1020167014409A KR20160079072A (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
CN201480059910.5A CN105793413A (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
SG11201603045VA SG11201603045VA (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
PH12016500782A PH12016500782A1 (en) 2013-11-01 2016-04-27 Suspension and clustering of human pluripotent stem cells for differentation into pancreatic endocrine cells
AU2018208707A AU2018208707A1 (en) 2013-11-01 2018-07-26 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361962158P 2013-11-01 2013-11-01
US61/962,158 2013-11-01
US13/998,974 2013-12-30
US13/998,974 US10377989B2 (en) 2012-12-31 2013-12-30 Methods for suspension cultures of human pluripotent stem cells

Publications (2)

Publication Number Publication Date
WO2015065524A2 WO2015065524A2 (en) 2015-05-07
WO2015065524A3 true WO2015065524A3 (en) 2015-08-13

Family

ID=53004904

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2014/038993 Ceased WO2015065524A2 (en) 2013-11-01 2014-05-21 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
PCT/US2014/042796 Ceased WO2015065537A1 (en) 2013-11-01 2014-06-17 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2014/042796 Ceased WO2015065537A1 (en) 2013-11-01 2014-06-17 Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells

Country Status (12)

Country Link
EP (2) EP3063268A4 (en)
JP (2) JP2016534731A (en)
KR (4) KR20160079072A (en)
CN (2) CN105793413A (en)
AU (4) AU2014342995C1 (en)
BR (1) BR112016009393A8 (en)
CA (2) CA2928639A1 (en)
MX (2) MX2016005657A (en)
PH (2) PH12016500783A1 (en)
RU (2) RU2689710C2 (en)
SG (2) SG11201603045VA (en)
WO (2) WO2015065524A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016005657A (en) * 2013-11-01 2017-01-05 Janssen Biotech Inc Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells.
CA3028422A1 (en) * 2016-06-23 2017-12-28 Tithon Biotech, Inc. Cells expressing parathyroid hormone 1 receptor and uses thereof
CN110167455B (en) 2016-11-10 2022-10-11 韦尔赛特公司 Cell delivery device containing PDX1 pancreatic endoderm cells and methods thereof
WO2018090084A1 (en) * 2016-11-16 2018-05-24 Cynata Therapeutics Limited Pluripotent stem cell assay
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
CN111246864A (en) * 2017-07-21 2020-06-05 森玛治疗公司 Repopulation of stem cell-derived pancreatic beta cells
JP7000896B2 (en) * 2017-08-23 2022-01-19 王子ホールディングス株式会社 Cell sheet forming member, method for manufacturing cell sheet forming member, and method for manufacturing cell sheet
BR112020013656A2 (en) * 2018-01-05 2020-12-01 Platelet Biogenesis, Inc. compositions and methods for producing megakaryocytes
JP2021510527A (en) * 2018-01-18 2021-04-30 エージェンシー フォー サイエンス， テクノロジー アンド リサーチ Methods for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture
KR102115360B1 (en) * 2018-05-30 2020-05-26 주식회사 바이블리오테카 Adult stem cell culture fluid and a producing method thereof
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
CA3139585C (en) 2019-05-31 2024-01-23 W. L. Gore & Associates, Inc. A biocompatible membrane composite
JP2022534545A (en) 2019-05-31 2022-08-01 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド biocompatible membrane composite
JP7328362B2 (en) 2019-05-31 2023-08-16 ダブリュ．エル．ゴア アンド アソシエイツ，インコーポレイティド Cell encapsulation device with controlled oxygen diffusion distance
WO2020243663A1 (en) 2019-05-31 2020-12-03 W. L. Gore & Associates, Inc. A biocompatible membrane composite
EP4022034A1 (en) * 2019-08-27 2022-07-06 United Therapeutics Corporation Methods and compositions for culturing alveolar cells
EP4025690A1 (en) 2019-09-05 2022-07-13 CRISPR Therapeutics AG Universal donor cells
EP4025224A1 (en) 2019-09-05 2022-07-13 CRISPR Therapeutics AG Universal donor cells
EP4061929A1 (en) * 2019-11-22 2022-09-28 Novo Nordisk A/S Spin-aggregated neural microspheres and the application thereof
EP4271796A1 (en) 2020-12-31 2023-11-08 CRISPR Therapeutics AG Universal donor cells
US20240191185A1 (en) * 2021-03-25 2024-06-13 Kaneka Corporation Method for producing pluripotent stem cell population
CN116218766A (en) * 2023-04-21 2023-06-06 北京意胜生物科技有限公司 A method for preparing pancreatic precursor cells, culture medium and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells
US20130224156A1 (en) * 2012-02-29 2013-08-29 Riken Method of producing human retinal pigment epithelial cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124721A1 (en) * 2001-11-09 2003-07-03 Bentley Cheatham Endocrine pancreas differentiation of adipose tissue-derived stromal cells and uses thereof
EP3441459B1 (en) * 2006-08-02 2021-03-17 Technion Research & Development Foundation Limited Methods of expanding embryonic stem cells in a suspension culture
WO2008056779A1 (en) * 2006-11-09 2008-05-15 Japan As Represented By The President Of International Medical Center Of Japan Method for culture and passage of primate embryonic stem cell, and method for induction of differentiation of the embryonic stem cell
BRPI0813787A2 (en) * 2007-07-01 2014-10-07 Lifescan Inc ISOLATED PLURIPOTENT STEM CELL CULTURE
US8716018B2 (en) * 2008-03-17 2014-05-06 Agency For Science, Technology And Research Microcarriers for stem cell culture
BRPI0914116A2 (en) * 2008-06-30 2019-09-17 Centocor Ortho Biotech Inc pluripotent stem cell differentiation
US8008075B2 (en) * 2008-11-04 2011-08-30 Viacyte, Inc. Stem cell aggregate suspension compositions and methods of differentiation thereof
ES2590036T3 (en) * 2009-08-12 2016-11-17 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
EP2582795B1 (en) * 2010-06-15 2017-04-12 Kyoto University Method for selecting human induced pluripotent stem cells
MX355077B (en) * 2010-08-31 2018-04-03 Janssen Biotech Inc Differentiation of human embryonic stem cells.
MY177150A (en) * 2011-02-28 2020-09-08 Stempeutics Res Malaysia Sdn Bhd Isolation and expansion of adult stem cells, their therapeutic composition and uses thereof
WO2013056072A1 (en) * 2011-10-13 2013-04-18 Wisconsin Alumni Research Foundation Generation of cardiomyocytes from human pluripotent stem cells
AU2013370228B2 (en) * 2012-12-31 2018-10-18 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
MX2016005657A (en) * 2013-11-01 2017-01-05 Janssen Biotech Inc Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
US20130189777A1 (en) * 2011-12-22 2013-07-25 Janssen Biotech, Inc. Differentiation of Human Embryonic Stem Cells into Single Hormonal Insulin Positive Cells
US20130224156A1 (en) * 2012-02-29 2013-08-29 Riken Method of producing human retinal pigment epithelial cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
EGUIZABAL ET AL.: "Complete Meiosis from Human Induced Pluripotent Stem Cells.", STEM CELLS., vol. 29, no. 8, 2011, pages 1186 - 95, XP055218519 *
MINAMI ET AL.: "A Small Molecule that Promotes Cardiac Differentiation of Human Pluripotent Stem Cells under Defined, Cytokine- and Xeno-free Conditions.", CELL REP., vol. 2, no. 5, November 2012 (2012-11-01), pages 1448 - 60., XP055097336 *
NIE ET AL.: "Scalable passaging of adherent human pluripotent stem cells.", PLOS ONE., vol. 9, no. 1, 2014, pages E88012, XP055218521 *
ROWLEY ET AL.: "Meeting Lot-Size Challenges of Manufacturing Adherent Cells for Therapy.", BIOPROCESS INT., vol. 10, no. 3, March 2012 (2012-03-01), pages 16 - 22, XP055218518 *
STACPOOLE ET AL.: "Efficient derivation of neural precursor cells, spinal motor neurons and midbrain dopaminergic neurons from human ES cells at 3% oxygen.", NAT PROTOC., vol. 6, no. 8, 2011, pages 1229 - 40, XP055218516 *
VIEIRA ET AL.: "Modulation of neuronal stem cell differentiation by hypoxia and reactive oxygen species.", PROG NEUROBIOL., vol. 93, no. 3, 2011, pages 444 - 55, XP028175304 *
WANT ET AL.: "The larger scale expansion of pluripotent stem cells for regenerative medicine purposes.", LOUGHBOROUGH UNIVERSITY INSTITUTIONAL REPOSITORY, SUBMITTED FOR PUBLICATION ON REGEN MED., vol. 7, no. 1, January 2012 (2012-01-01), pages 71 - 84, XP055354028, Retrieved from the Internet <URL:https://dspace.boro.ac.uk/dspace- jspui/bitstream/2134/11041/6/HewittVersion.pdf> [retrieved on 20140826] *
YANG ET AL.: "Evaluation of human MSCs cell cycle, viability and differentiation in micromass culture.", BIORHEOLOGY., vol. 43, no. 3-4, 2006, pages 489 - 96, XP055339090, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pubmed/16912420> [retrieved on 20140917] *
ZUSCIK ET AL.: "Regulation of chondrogenesis and chondrocyte differentiation by stress.", J CLIN INVEST., vol. 118, no. 2, 2008, pages 429 - 38, XP055218520 *

Also Published As

Publication number Publication date
RU2016121404A (en) 2017-12-04
RU2016121404A3 (en) 2018-03-29
PH12016500783A1 (en) 2016-06-13
EP3063268A2 (en) 2016-09-07
WO2015065524A2 (en) 2015-05-07
CA2928741A1 (en) 2015-05-07
RU2016121409A3 (en) 2018-03-29
WO2015065537A1 (en) 2015-05-07
AU2014343007C1 (en) 2018-08-09
EP3063268A4 (en) 2017-11-29
KR20180130001A (en) 2018-12-05
SG11201603045VA (en) 2016-05-30
AU2018208707A1 (en) 2018-08-16
EP3063269A4 (en) 2017-07-12
AU2014342995B2 (en) 2018-04-26
SG11201603047PA (en) 2016-05-30
MX2016005657A (en) 2017-01-05
CN105683362A (en) 2016-06-15
KR20180128529A (en) 2018-12-03
AU2014343007A1 (en) 2016-05-05
JP2017500013A (en) 2017-01-05
AU2018208717A1 (en) 2018-08-16
BR112016009393A8 (en) 2020-03-24
PH12016500782A1 (en) 2016-06-13
MX2016005658A (en) 2017-01-05
EP3063269A1 (en) 2016-09-07
AU2014342995A1 (en) 2016-05-05
KR20160079071A (en) 2016-07-05
KR20160079072A (en) 2016-07-05
CN105793413A (en) 2016-07-20
RU2016121409A (en) 2017-12-04
CA2928639A1 (en) 2015-05-07
AU2014342995C1 (en) 2018-08-09
AU2014343007B2 (en) 2018-04-26
RU2689710C2 (en) 2019-05-29
JP2016534731A (en) 2016-11-10

Similar Documents

Publication Publication Date Title
WO2015065524A3 (en) Suspension and clustering of human pluripotent stem cells for differentiation into pancreatic endocrine cells
IL285922A (en) Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
HK1217727A1 (en) Suspension and clustering of human pluripotent cells for differentiation into pancreatic endocrine cells
WO2014124087A8 (en) Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
WO2014100779A8 (en) Methods for production of platelets from pluripotent stem cells and compositions thereof
PH12018501294A1 (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells
WO2012030539A3 (en) Differentiation of human embryonic stem cells
WO2014153069A3 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
EP3145517A4 (en) Functional oligodendrocytes derived from pluripotent stem cells and methods of making and using the same
WO2016162747A3 (en) Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases
HK1222205A1 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
PH12014501426A1 (en) Induced pluripotent stem cells from human umbilical cord tissue-derived cells
WO2016061071A8 (en) Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures
PH12014502686A1 (en) Differentiation of human embryonic stem cells into pancreatic endoderm
WO2012030538A3 (en) Differentiation of human embryonic stem cells
WO2012092049A8 (en) Brown adipocyte modification
WO2014113704A3 (en) Enhanced differentiation of mesenchymal stem cells
MX2016014008A (en) Method for differentiation of pluripotent stem cells into cardiomyocytes.
SG11201900989QA (en) Method for inducing differentiation of pluripotent stem cells in vitro
KR101896803B9 (en) Method for increasing the rate of inducing differentiation of human pluripotent stem cells to mesenchymal stem cells and mesenchymal stem cells produced by thereof
PH12014501383A1 (en) Induced pluripotent stem cells prepared from human kidney-derived cells
WO2013188407A3 (en) In vitro differentiation of motor neuron progenitors from human induced pluripotent stem cells and cryopreservation
EP3652200A4 (en) Induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation using landmark transcription factors
EP3194573A4 (en) Mammalian pluripotent stem cells, methods for their production, and uses thereof
WO2014146057A3 (en) Mesenchymal stem cells

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2928639

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12016500782

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2016527338

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/005657

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2014342995

Country of ref document: AU

Date of ref document: 20140521

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016009399

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: IDP00201603594

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 20167014409

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016121409

Country of ref document: RU

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014857034

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014857034

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14857034

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016009399

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160427